(Q46841076)

25 December 2017

title

Protection of mice from Shiga toxin-2 toxemia by mucosal vaccine of Shiga toxin 2B-His with Escherichia coli enterotoxin (English)

1 reference

25 December 2017

1 reference

Takao Tsuji

1

1 reference

25 December 2017

Takeshi Shimizu

2

1 reference

25 December 2017

Keiko Sasaki

3

1 reference

25 December 2017

Yoshiyasu Shimizu

4

1 reference

25 December 2017

Kentaro Tsukamoto

5

1 reference

25 December 2017

Hideyuki Arimitsu

6

1 reference

25 December 2017

Sadayuki Ochi

7

1 reference

25 December 2017

Satoshi Sugiyama

8

1 reference

25 December 2017

Koki Taniguchi

9

1 reference

25 December 2017

Paola Neri

10

1 reference

25 December 2017

Hiroshi Mori

11

1 reference

25 December 2017

language of work or name

English

0 references

publication date

3 December 2007

1 reference

25 December 2017

published in

Vaccine

1 reference

25 December 2017

volume

26

1 reference

25 December 2017

issue

4

1 reference

25 December 2017

page(s)

469-476

1 reference

25 December 2017

The role of Shiga-toxin-producing Escherichia coli in hemorrhagic colitis and hemolytic uremic syndrome

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Infection by Shiga toxin-producing Escherichia coli: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Escherichia coli O157:H7 infection in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Epidemic of gastrointestinal tract infection including hemorrhagic colitis attributable to Shiga toxin 1-producing Escherichia coli O118:H2 at a junior high school in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2: Microbiological aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Immunoprophylactic potential of cloned Shiga toxin 2 B subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Relationship between a low toxicity of the mutant A subunit of enterotoxigenic Escherichia coli enterotoxin and its strong adjuvant action.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

The serine 31 residue of the B subunit of Shiga toxin 2 is essential for secretion in enterohemorrhagic Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus calmette-guerin in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1‐type helper T cells with a single nasal coadministration in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Single-step method for purification of Shiga toxin-1 B subunit using receptor-mediated affinity chromatography by globotriaosylceramide-conjugated octyl sepharose CL-4B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

inferred from DOI database lookup

7 January 2021

based on heuristic

Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

inferred from DOI database lookup

7 January 2021

based on heuristic

Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.038

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2007.11.038

1 reference

25 December 2017

1 reference

25 December 2017